Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Data at Week 24 of Treatment with Taspoglutide Presented at EASD
October 11, 2010
- Anti-Flu Virus Drug Inavir Included in NHI Price List
October 11, 2010
- Dr Boku Expresses Hope for Everolimus in 2nd-Line Therapy for Stomach Cancer
October 11, 2010
- Approval of Takepron for Prevention of NSAID-Induced Ulcers Welcome: Prof. Soen
October 11, 2010
- Astellas Applies for Darexaban in Japan
October 11, 2010
- Daiichi Sankyo Espha Aims at Sales of ¥5 Bil. in 1st Year
October 11, 2010
- Asthma Should Be Treated First in COPD Patients with Asthma: Prof. Nagai
October 11, 2010
- FDA Extends Review Period for Avastin for Advanced Breast Cancer
October 11, 2010
- Abraxan Makes Outpatients' Life Easier: Taiho
October 11, 2010
- Zeria, Astellas Apply for Acotiamide in Japan
October 11, 2010
- Astellas Aims at Overseas Vaccines Market
October 11, 2010
- Revolade Recommended for Approval
October 11, 2010
- ASKA, Senju Create Ceolia Pharma
October 11, 2010
- Fingolimod Approved in the US: Novartis
October 11, 2010
- CMIC Licenses Ecallantide for HAE from Dyax
October 11, 2010
- Gov't, Industry to Discuss How to Ensure Stable Supply of Molybdenum
October 11, 2010
- Panelists Call For Support of Ventures: BioJapan 2010
October 11, 2010
- L-FABP Testing Agent Approved: CMIC
October 11, 2010
- Mediceo to Build Cost-Conscious Company: President Watanabe
October 11, 2010
- Roche to Seek More Alliance Opportunities to Develop Innovative Drugs
October 11, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…